These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Network biomarkers for the diagnosis and treatment of movement disorders. Poston KL; Eidelberg D Neurobiol Dis; 2009 Aug; 35(2):141-7. PubMed ID: 19013242 [TBL] [Abstract][Full Text] [Related]
27. Biomarkers in Parkinson's disease: an update. Shtilbans A; Henchcliffe C Curr Opin Neurol; 2012 Aug; 25(4):460-5. PubMed ID: 22772875 [TBL] [Abstract][Full Text] [Related]
29. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Albrecht S; Buerger E Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998 [TBL] [Abstract][Full Text] [Related]
30. Can we image premotor Parkinson disease? Marek K; Jennings D Neurology; 2009 Feb; 72(7 Suppl):S21-6. PubMed ID: 19221310 [TBL] [Abstract][Full Text] [Related]
31. New small molecules for the treatment of Parkinson's disease. Müller T Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881 [TBL] [Abstract][Full Text] [Related]
32. Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. Seibyl J; Russell D; Jennings D; Marek K Semin Nucl Med; 2012 Nov; 42(6):406-14. PubMed ID: 23026362 [TBL] [Abstract][Full Text] [Related]
33. Biomarkers for the diagnosis and management of Parkinson's disease. Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844 [TBL] [Abstract][Full Text] [Related]
34. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Hung AY; Schwarzschild MA Curr Opin Neurol; 2007 Aug; 20(4):477-83. PubMed ID: 17620885 [TBL] [Abstract][Full Text] [Related]
35. Treatment options for early Parkinson's disease. Stacy M; Brownlee HJ Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572 [TBL] [Abstract][Full Text] [Related]
36. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Olanow CW Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316 [TBL] [Abstract][Full Text] [Related]
37. Why have we failed to achieve neuroprotection in Parkinson's disease? Olanow CW; Kieburtz K; Schapira AH Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580 [TBL] [Abstract][Full Text] [Related]
38. Trial designs used to study neuroprotective therapy in Parkinson's disease. Lang AE; Melamed E; Poewe W; Rascol O Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060 [TBL] [Abstract][Full Text] [Related]